Jazz Pharmaceuticals Reports 19% Revenue Growth to $1.1B, Zanidatamab Granted Priority Review
In Q1 2026 Jazz Pharmaceuticals reported total revenues of $1.1 billion, up 19% year-over-year, with GAAP EPS of $4.43 and non-GAAP EPS of $6.34. The FDA granted Priority Review to Zanidatamab’s HER2+ first-line gastroesophageal adenocarcinoma sBLA, targeting an August 25, 2026 PDUFA date.
1. Q1 Financial Highlights
Jazz delivered total Q1 2026 revenues of $1.1 billion, up 19% year-over-year, driven by product sales growth. GAAP EPS was $4.43 and non-GAAP EPS was $6.34, with cash from operations of $408 million and reaffirmed full-year revenue and expense guidance.
2. Commercial Performance
Xywav net sales increased 18% to $408 million with 425 net patient adds and 16,600 active patients, while Epidiolex net sales rose 15% to $250 million and Zepzelca sales jumped 60% to $101 million. Modeyso generated $41 million since its August 2025 launch, and Ziihera contributed $13 million in biliary tract cancer sales.
3. Pipeline and Regulatory Updates
The FDA accepted the zanidatamab sBLA for first-line HER2+ gastroesophageal adenocarcinoma under the Priority Review program, with a PDUFA date set for August 25, 2026. Phase 3 HERIZON-GEA-01 trial results support zanidatamab’s use, and multiple registrational studies, including metastatic breast cancer, are ongoing.